Document Detail


Retinal pigment epithelium tears in age-related macular degeneration treated with antiangiogenic drugs: a controlled study with long follow-up.
MedLine Citation:
PMID:  22710369     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Purpose: To study whether anti-vascular endothelial growth factor (VEGF) therapy improves visual acuity (VA) in patients with exudative age-related macular degeneration (AMD) complicated with retinal pigment epithelium (RPE) tears. Methods: Retrospective case-control series. Group I (control group) included 9 patients with RPE tears that received no treatment, and group II (intervention group) incorporated 12 patients treated with anti-VEGF. Results: A statistically significant difference was found in VA between the groups from the 3rd month to the final follow-up (p = 0.034). Final VA improved in the treatment group (p = 0.015). No differences were found in central macular thickness between the groups either before or after treatment. Mean number of injections in group II was 5.75 (SD = 1.19). Most patients presented a grade 3 rip. All lesions were inactive at the end of follow-up in group II and 1 remained active in group I. The number of final atrophic/disciform scars was 6/8 in group I and 7/5 in group II. Conclusions: RPE tears treated with antiangiogenic drugs experienced functional benefit. To the authors' knowledge, this is the first controlled series reporting effectiveness of suppression of neovascular activity with antiangiogenic treatment after RPE rip in AMD.
Authors:
Rosa M Coco; M Rosa Sanabria; Arturo G Hernandez; Marta Fernández Muñoz
Related Documents :
17342569 - Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbid...
20970749 - Preoperative use of incentive spirometry does not affect postoperative lung function in...
11689389 - Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a doub...
15318989 - Evaluation of quality of life and metabolic improvement after jejunoileal bypass in a c...
18098399 - Postoperative morbidity of biliopancreatic diversion depending on common limb length.
3667069 - Gastric banding for morbid obesity: early results.
9584249 - Astigmatism induced by intrastromal corneal suture after small incision phacoemulsifica...
23848349 - Proximal junctional kyphosis and clinical outcomes in adult spinal deformity surgery wi...
19190059 - Review of kinemax knee arthroplasty performed at the nhs treatment centre, weston-super...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2012-06-15
Journal Detail:
Title:  Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde     Volume:  228     ISSN:  1423-0267     ISO Abbreviation:  Ophthalmologica     Publication Date:  2012  
Date Detail:
Created Date:  2012-07-31     Completed Date:  2012-10-05     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0054655     Medline TA:  Ophthalmologica     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  78-83     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Institute of Applied Ophthalmobiology (IOBA), University of Valladolid, Valladolid, Spain. rosa@ioba.med.uva.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage
Aptamers, Nucleotide / administration & dosage
Case-Control Studies
Female
Fluorescein Angiography
Follow-Up Studies
Humans
Intravitreal Injections
Macular Degeneration / drug therapy*,  physiopathology
Male
Middle Aged
Retinal Perforations / drug therapy*,  physiopathology
Retinal Pigment Epithelium
Retrospective Studies
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Aptamers, Nucleotide; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/pegaptanib; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interaction of (-)-Epigallocatechin Gallate with Lysozyme-Conjugated Silver Nanoparticles.
Next Document:  Clinical Profiles, Endoscopic and Laboratory Features and Associated Factors in Patients with Autoim...